Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203
Category: Chemotherapy
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Given the heterogeneity of acute myeloid leukemia patients, it is necessary to identify patients considered fit for intensive therapy but who will …